Evidence map›Paper›PMID 27872498›Full record

ArticleLeukemia2017

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.

J V Jovanovic, M C Chillón, C Vincent-Fabert, R Dillon, E Voisset, N C Gutiérrez, R G Sanz, A A M Lopez, Y G Morgan, J Lok and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Pharmaceuticals (Basel, Switzerland) · 2021
    Article
  10. Review
  11. Review
  12. Article
  13. PLZF-RARCancers · 2020
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

J V JovanovicKing's College London, Faculty of Life Sciences and Medicine, Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, London, UK.
M C ChillónHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC, (USAL-CSIC) Salamanca, Spain.
C Vincent-FabertCentre de Recherche en Cancérologie de Marseille U1068 INSERM, UMR 7258 CNRS, Aix-Marseille Université, Marseille, France.
R DillonKing's College London, Faculty of Life Sciences and Medicine, Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, London, UK.
E VoissetKing's College London, Faculty of Life Sciences and Medicine, Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, London, UK.
N C GutiérrezHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC, (USAL-CSIC) Salamanca, Spain.
R G SanzHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC, (USAL-CSIC) Salamanca, Spain.
A A M LopezHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC, (USAL-CSIC) Salamanca, Spain.
Y G MorganMolecular Oncology Section, Cancer Genetics, Viapath, Guy's Hospital, London, UK.
J LokMolecular Oncology Section, Cancer Genetics, Viapath, Guy's Hospital, London, UK.
E SolomonKing's College London, Faculty of Life Sciences and Medicine, Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, London, UK.
E DuprezCentre de Recherche en Cancérologie de Marseille U1068 INSERM, UMR 7258 CNRS, Aix-Marseille Université, Marseille, France.
M G DíazHospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC, (USAL-CSIC) Salamanca, Spain.
D GrimwadeKing's College London, Faculty of Life Sciences and Medicine, Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultCarrier ProteinsChromosomes, Human, Pair 15Chromosomes, Human, Pair 17DNA-Binding ProteinsHematopoietic Stem CellsHumansLeukemia, Promyelocytic, AcuteMaleNuclear ProteinsOncogene Proteins, FusionRetinoic Acid Receptor alphaRetinoidsStem CellsTranscription FactorsTranslocation, GeneticCarrier ProteinsDNA-Binding ProteinsIRF2BP2 protein, humanNuclear ProteinsOncogene Proteins, FusionRARA protein, humanRetinoic Acid Receptor alphaRetinoidsTranscription Factors

Identifiers

PMID27872498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.